Currently, there are 128.67M common shares owned by the public and among those 104.39M shares have been available to trade.
The company’s stock has a 5-day price change of -48.64% and -67.77% over the past three months. HUMA shares are trading -66.24% year to date (YTD), with the 12-month market performance down to -45.00% lower. It has a 12-month low price of $1.76 and touched a high of $9.97 over the same period. HUMA has an average intraday trading volume of 2.97 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -40.09%, -52.22%, and -66.97% respectively.
Institutional ownership of Humacyte Inc (NASDAQ: HUMA) shares accounts for 33.28% of the company’s 128.67M shares outstanding.
It has a market capitalization of $257.70M and a beta (3y monthly) value of 1.58. The earnings-per-share (ttm) stands at -$1.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.93% over the week and 9.64% over the month.
Analysts forecast that Humacyte Inc (HUMA) will achieve an EPS of -0.21 for the current quarter, -0.2 for the next quarter and -0.24 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.26 while analysts give the company a high EPS estimate of -0.26. Comparatively, EPS for the current quarter was -0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 39.23%, and 56.90% over the next financial year.
Looking at the support for the HUMA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 20, 2024, with the firm’s price target at $12-$15. H.C. Wainwright coverage for the Humacyte Inc (HUMA) stock in a research note released on December 11, 2023 offered a Buy rating with a price target of $6. Piper Sandler was of a view on August 14, 2023 that the stock is Neutral, while Cantor Fitzgerald gave the stock Overweight rating on June 22, 2023, issuing a price target of $6. Piper Sandler on their part issued Underweight rating on May 16, 2022.
